Skip to content

May 7, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Regulatory
FDA reverses course on Atara, Pierre Fabre’s twice-rejected cell therapy after Prasad’s exit

Regulatory

FDA reverses course on Atara, Pierre Fabre’s twice-rejected cell therapy after Prasad’s exit

BioSpace

The FDA turned away Ebvallo in January, taking issue with the design of the registrational trial.

Read full story

pharminent May 7, 2026 (Last updated: May 7, 2026)

BioSpace

The FDA turned away Ebvallo in January, taking issue with the design of the registrational trial.

Read full story

Post navigation

Previous: Angelini inks $4.1B Catalyst buy to enter US rare disease market

Related Stories

Regulatory

Bayer plans filings for cardiac amyloidosis imaging agent

pharminent May 7, 2026

Regulatory

FDA Expands AI Capabilities and Completes Data Platform Consolidation

pharminent May 6, 2026

Regulatory

FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight

pharminent May 6, 2026

You May Have Missed

Regulatory

FDA reverses course on Atara, Pierre Fabre’s twice-rejected cell therapy after Prasad’s exit

pharminent May 7, 2026

M&A / Deals

Angelini inks $4.1B Catalyst buy to enter US rare disease market

pharminent May 7, 2026

Regulatory

Bayer plans filings for cardiac amyloidosis imaging agent

pharminent May 7, 2026

M&A / Deals

Roche buys AI-powered diagnostics player PathAI

pharminent May 7, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.